Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Liposome Tech looks for a new crew

Liposome Technology Inc. completed the first phase of a management restructuring, with the announcement that CFO Peter Leigh will leave the Menlo Park, Calif., company. Chairman and CEO Nick Arvanitidis already has said he will retire as of July 1, and Medical Director Richard Mamelock has resigned.

The departures leave the company's

Read the full 513 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE